X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9065) 9065
Book Review (1005) 1005
Publication (997) 997
Book Chapter (16) 16
Conference Proceeding (11) 11
Magazine Article (7) 7
Dissertation (6) 6
Data Set (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (8608) 8608
animals (5048) 5048
humans (5030) 5030
male (4958) 4958
pyrazoles - pharmacology (4102) 4102
female (3052) 3052
pyrazoles - administration & dosage (2946) 2946
rats (2656) 2656
pyrazoles - therapeutic use (2292) 2292
pharmacology & pharmacy (2025) 2025
mice (1839) 1839
celecoxib (1665) 1665
dose-response relationship, drug (1572) 1572
middle aged (1546) 1546
aged (1369) 1369
pyrazoles - adverse effects (1311) 1311
adult (1272) 1272
piperidines - pharmacology (1253) 1253
oncology (1141) 1141
neurosciences (1083) 1083
administration, oral (999) 999
treatment outcome (964) 964
rats, sprague-dawley (926) 926
sulfonamides - administration & dosage (756) 756
analysis (753) 753
time factors (748) 748
abridged index medicus (741) 741
rats, wistar (734) 734
receptor, cannabinoid, cb1 - antagonists & inhibitors (708) 708
pyrazoles - pharmacokinetics (663) 663
disease models, animal (651) 651
pyrazoles (643) 643
sulfonamides - pharmacology (633) 633
cancer (629) 629
hematology (627) 627
care and treatment (609) 609
sulfonamides - therapeutic use (609) 609
expression (604) 604
research (591) 591
pyrazoles - chemistry (586) 586
article (567) 567
drug therapy (536) 536
aged, 80 and over (504) 504
cell line, tumor (478) 478
pyridones - administration & dosage (477) 477
rivaroxaban (473) 473
dabigatran (468) 468
medicine & public health (446) 446
chemistry, medicinal (439) 439
biochemistry & molecular biology (430) 430
pyridones - therapeutic use (429) 429
mice, inbred c57bl (428) 428
brain (426) 426
double-blind method (417) 417
anticoagulants (415) 415
risk factors (413) 413
sulfonamides - adverse effects (413) 413
cox-2 inhibitors (412) 412
activation (409) 409
drug administration schedule (399) 399
drug interactions (395) 395
nonsteroidal antiinflammatory drugs (395) 395
anticoagulants - administration & dosage (388) 388
cardiac & cardiovascular systems (388) 388
pyrimidines - pharmacology (386) 386
inhibition (384) 384
apoptosis (382) 382
rodents (382) 382
health aspects (380) 380
apixaban (379) 379
rat (371) 371
anticoagulants - therapeutic use (369) 369
dosage and administration (367) 367
endocannabinoids (367) 367
cyclooxygenase inhibitors - pharmacology (361) 361
warfarin (361) 361
prevention (359) 359
receptor, cannabinoid, cb1 - metabolism (352) 352
therapy (350) 350
medicine, general & internal (349) 349
pyridines - administration & dosage (346) 346
pyrimidines - administration & dosage (344) 344
safety (339) 339
pyridines - pharmacology (338) 338
inflammation (337) 337
psychiatry (336) 336
pyridines - therapeutic use (334) 334
apoptosis - drug effects (333) 333
morpholines - pharmacology (328) 328
in-vitro (326) 326
chemotherapy (323) 323
signal transduction - drug effects (322) 322
pharmacology/toxicology (321) 321
behavior, animal - drug effects (320) 320
efficacy (320) 320
pharmacology (320) 320
cell proliferation - drug effects (319) 319
pyridones - adverse effects (319) 319
dogs (317) 317
toxicology (314) 314
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8796) 8796
German (73) 73
French (51) 51
Japanese (30) 30
Italian (28) 28
Russian (23) 23
Spanish (19) 19
Chinese (18) 18
Czech (10) 10
Hungarian (9) 9
Norwegian (7) 7
Swedish (6) 6
Danish (4) 4
Portuguese (4) 4
Dutch (2) 2
Polish (2) 2
Bulgarian (1) 1
Finnish (1) 1
Korean (1) 1
Lithuanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 08/2015, Volume 21, Issue 16, pp. 3705 - 3715
Purpose: Bruton's tyrosine kinase (BTK) is a critical enzyme in the B-cell receptor pathway and is inhibited by ibrutinib due to covalent binding to the kinase... 
B-CELL RECEPTOR | TUMOR PROLIFERATION | BRUTONS TYROSINE KINASE | CLL | ONCOLOGY | BCL-2 INHIBITOR | INITIAL THERAPY | IN-VIVO | PCI-32765 | KINASE INHIBITOR IBRUTINIB | SINGLE-ARM | Piperazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Apoptosis - drug effects | Humans | Neoplastic Cells, Circulating - metabolism | Male | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Purines - administration & dosage | Bendamustine Hydrochloride - administration & dosage | Protein-Tyrosine Kinases - genetics | Female | bcl-X Protein - biosynthesis | Protein-Tyrosine Kinases - biosynthesis | B-Cell Activating Factor - biosynthesis | Neoplastic Cells, Circulating - drug effects | Pyrimidines - administration & dosage | Gene Expression Regulation, Leukemic - drug effects | Nitrophenols - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - biosynthesis | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Pyrazoles - administration & dosage | B-Cell Activating Factor - genetics | Biphenyl Compounds - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Isoquinolines - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - genetics | Sulfonamides - administration & dosage | Index Medicus
Journal Article
Journal Article
Journal Article
Journal Article
Stroke, ISSN 0039-2499, 06/2013, Volume 44, Issue 6, pp. 1676 - 1681
Background and Purpose-To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral... 
Intracranial hemorrhage | Stroke | Anticoagulation | Markov model | Cost-effectiveness | Atrial fibrillation | cost-effectiveness | ANTICOAGULATION CONTROL | QUALITY | anticoagulation | stroke | ASPIRIN | CLINICAL NEUROLOGY | PROPHYLAXIS | atrial fibrillation | HEART-DISEASE | BENEFIT | THERAPY | intracranial hemorrhage | SCORES | PERIPHERAL VASCULAR DISEASE | UPDATE | UTILITY | Thiophenes - therapeutic use | Markov Chains | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | United States | Humans | Anticoagulants - economics | Thiophenes - administration & dosage | Warfarin - economics | Benzimidazoles - economics | Dabigatran | Morpholines - economics | Warfarin - administration & dosage | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - economics | Stroke - epidemiology | Thiophenes - economics | Pyridones - economics | beta-Alanine - analogs & derivatives | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Quality-Adjusted Life Years | Stroke - prevention & control | Administration, Oral | Morpholines - administration & dosage | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - administration & dosage | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Models, Statistical | Pyrazoles - economics | Pyrazoles - administration & dosage | Cost-Benefit Analysis | Aged | Pyridones - therapeutic use | Cohort Studies | Index Medicus
Journal Article
Journal Article
Blood, ISSN 0006-4971, 08/2015, Volume 126, Issue 6, pp. 721 - 732
Waldenstrom macroglobulinemia (WM) is a B-cell neoplasm manifested by the accumulation of clonal immunoglobulin (Ig)M-secreting lymphoplasmacytic cells. MYD88... 
CONSENSUS PANEL RECOMMENDATIONS | 2ND INTERNATIONAL WORKSHOP | L265P SOMATIC MUTATION | MULTIPLE-MYELOMA | RITUXIMAB THERAPY | IMMUNOGLOBULIN-M | MYD88 L265P | LYMPHOPROLIFERATIVE DISORDERS | LYMPHOPLASMACYTIC CELLS | INHIBITOR EVEROLIMUS | HEMATOLOGY | Cyclophosphamide - administration & dosage | Nitrogen Mustard Compounds - administration & dosage | Waldenstrom Macroglobulinemia - therapy | Humans | Middle Aged | Pyrazines - administration & dosage | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Transplantation, Autologous | Molecular Targeted Therapy | Waldenstrom Macroglobulinemia - pathology | Adult | Receptors, CXCR4 - genetics | B-Lymphocytes - pathology | Boronic Acids - administration & dosage | Everolimus | B-Lymphocytes - metabolism | Waldenstrom Macroglobulinemia - diagnosis | Immunoglobulin M - genetics | Gene Expression | Genetic Predisposition to Disease | Sirolimus - analogs & derivatives | Bortezomib | Pyrimidines - administration & dosage | Myeloid Differentiation Factor 88 - genetics | Antineoplastic Combined Chemotherapy Protocols | Hematopoietic Stem Cell Transplantation | Rituximab | Vidarabine - analogs & derivatives | Cladribine - administration & dosage | Plasmapheresis | Receptors, CXCR4 - metabolism | B-Lymphocytes - drug effects | Sirolimus - administration & dosage | Pyrazoles - administration & dosage | Bendamustine Hydrochloride | Aged | Oligopeptides - administration & dosage | Vidarabine - administration & dosage | Myeloid Differentiation Factor 88 - metabolism | Waldenstrom Macroglobulinemia - genetics | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2016, Volume 34, Issue 7, pp. 661 - 668
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2017, Volume 69, Issue 23, pp. 2779 - 2790
Abstract Background Dose reduction of non–vitamin K antagonist oral anticoagulants (NOACs) is indicated in patients with atrial fibrillation (AF) with renal... 
Cardiovascular | Internal Medicine | kidney disease | dose | bleeding | embolism | stroke | CARDIAC & CARDIOVASCULAR SYSTEMS | SAFETY | RIVAROXABAN | RISK | APIXABAN | MDRD | CARE | COCKCROFT-GAULT | DABIGATRAN | WARFARIN | United States - epidemiology | Dabigatran - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Male | Antithrombins - administration & dosage | Rivaroxaban - administration & dosage | Factor Xa Inhibitors - administration & dosage | Incidence | Dose-Response Relationship, Drug | Young Adult | Pyridones - administration & dosage | Time Factors | Aged, 80 and over | Adult | Female | Renal Insufficiency - complications | Stroke - epidemiology | Retrospective Studies | Vitamin K | Stroke - prevention & control | Hemorrhage - epidemiology | Administration, Oral | Atrial Fibrillation - drug therapy | Atrial Fibrillation - complications | Treatment Outcome | Pyrazoles - administration & dosage | Stroke - etiology | Adolescent | Aged | Hemorrhage - chemically induced | Stroke (Disease) | Medical policy | Care and treatment | Atrial fibrillation | Health care industry | Anticoagulants (Medicine) | Kidney diseases | Medical research | Chronic kidney failure | Medicine, Experimental | Heart | Cardiac arrhythmia | Renal function | Embolisms | Indication | Impairment | Risk | Data bases | Bleeding | Training | Prevention | Confidence intervals | Fibrillation | Databases | Ischemia | Safety | Drug dosages | Anticoagulants | Dosing | Stroke | Statistical analysis | Regression | Hazards | Labels | Marking | Patients | Embolism | Disease prevention | Oral cavity | Renal failure | Clinical medicine | Kidney transplantation | Index Medicus | Abridged Index Medicus
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
Journal of the American Heart Association, ISSN 2047-9980, 06/2016, Volume 5, Issue 6, p. n/a
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2012, Volume 60, Issue 8, pp. 738 - 746
Objectives This study sought to perform an indirect comparison analysis of dabigatran etexilate (2 doses), rivaroxaban, and apixaban for their relative... 
Cardiovascular | Internal Medicine | indirect comparisons | dabigatran | atrial fibrillation | rivaroxaban | apixaban | stroke prevention | NETWORK | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | METAANALYSIS | RISK | THERAPY | WARFARIN | ASSOCIATION | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | Thiophenes - adverse effects | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Dabigatran | Pyridones - administration & dosage | Rivaroxaban | Clinical Trials, Phase III as Topic | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Female | Benzimidazoles - adverse effects | Odds Ratio | Morpholines - adverse effects | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Pyrazoles - adverse effects | Pyridines - therapeutic use | Stroke - prevention & control | Pyridines - administration & dosage | Administration, Oral | Morpholines - administration & dosage | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Pyrazoles - administration & dosage | Stroke - etiology | Aged | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects | Stroke (Disease) | Usage | Analysis | Atrial fibrillation | Anticoagulants (Medicine) | Universities and colleges | Cardiology | Anticoagulants | Cardiac arrhythmia | Stroke | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article